CytomX Therapeutics Inc (NASDAQ:CTMX) Director Frederick W. Gluck sold 16,181 shares of the firm’s stock in a transaction dated Friday, March 2nd. The stock was sold at an average price of $30.00, for a total transaction of $485,430.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.
CytomX Therapeutics Inc (NASDAQ:CTMX) traded up $1.20 during trading on Wednesday, hitting $34.24. 659,772 shares of the stock traded hands, compared to its average volume of 368,553. CytomX Therapeutics Inc has a 1 year low of $13.00 and a 1 year high of $35.00. The company has a market capitalization of $1,321.27, a P/E ratio of -28.68 and a beta of 0.76.
Several institutional investors have recently bought and sold shares of CTMX. Macquarie Group Ltd. bought a new stake in shares of CytomX Therapeutics during the third quarter valued at approximately $107,000. Bank of Montreal Can bought a new stake in shares of CytomX Therapeutics during the fourth quarter valued at approximately $124,000. Cubist Systematic Strategies LLC bought a new stake in shares of CytomX Therapeutics during the second quarter valued at approximately $174,000. Voya Investment Management LLC bought a new stake in shares of CytomX Therapeutics during the second quarter valued at approximately $203,000. Finally, MetLife Investment Advisors LLC bought a new stake in shares of CytomX Therapeutics during the fourth quarter valued at approximately $245,000. 78.50% of the stock is owned by hedge funds and other institutional investors.
CTMX has been the subject of several analyst reports. ValuEngine downgraded shares of CytomX Therapeutics from a “hold” rating to a “sell” rating in a research note on Friday, December 1st. Zacks Investment Research downgraded shares of CytomX Therapeutics from a “hold” rating to a “sell” rating in a research note on Monday, February 5th. Citigroup initiated coverage on shares of CytomX Therapeutics in a research note on Friday, January 5th. They issued a “buy” rating and a $40.00 price objective for the company. BidaskClub downgraded shares of CytomX Therapeutics from a “buy” rating to a “hold” rating in a research note on Thursday, December 7th. Finally, Cantor Fitzgerald set a $40.00 price objective on shares of CytomX Therapeutics and gave the stock a “buy” rating in a research note on Thursday, March 8th. Three analysts have rated the stock with a sell rating, two have assigned a hold rating, eight have given a buy rating and one has given a strong buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus target price of $35.67.
ILLEGAL ACTIVITY NOTICE: This article was originally published by The Lincolnian Online and is the property of of The Lincolnian Online. If you are reading this article on another site, it was illegally stolen and republished in violation of U.S. and international trademark & copyright law. The legal version of this article can be viewed at https://www.thelincolnianonline.com/2018/03/14/cytomx-therapeutics-inc-ctmx-director-frederick-w-gluck-sells-16181-shares.html.
About CytomX Therapeutics
CytomX Therapeutics, Inc is a clinical-stage, oncology-focused biopharmaceutical company. The Company uses its Probody technology platform to create cancer immunotherapies against clinically validated targets, as well as to develop cancer therapeutics against difficult-to-drug targets. Its pipeline is focused on the development of therapies in a set of modalities: Probody cancer immunotherapies, Probody drug conjugates, T-cell engaging Probody bispecifics and ProCAR-NK cell therapies.
Receive News & Ratings for CytomX Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytomX Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.